---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-037474"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:06:26.399541+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oramed Pharmaceuticals completes sale of subsidiary Oratech to Lifeward and purchases $9M convertible notes

## Summary
- Lifeward acquired Oramed's wholly-owned subsidiary Oratech for 1,250,363 ordinary shares, 1,006,113 pre-funded warrants, and share purchase warrants.
- Oramed purchased $9,000,000 aggregate principal of Lifeward senior secured convertible notes with initial conversion price of $5.40 per share.
- Oramed also received purchase agreement warrants to buy up to 1,666,666 Lifeward ordinary shares at $5.40 per share.
- Oramed is entitled to ongoing revenue sharing payments equal to 4% of net revenue from Lifeward's ReWalk exoskeleton products.

## SEC filing metadata
- accession: 0001213900-26-037474
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390026037474/0001213900-26-037474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390026037474/ea0284244-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-037474
- JSON: https://secwatch.observer/filing/0001213900-26-037474.json
- Plain text: https://secwatch.observer/filing/0001213900-26-037474.txt

## Source-grounded claims
- claim_id: 850f7e0cb74d84a87b4fa3fbb1ee94f91f59d41a
  claim: ORAMED PHARMACEUTICALS INC. completed a disposition involving Lifeward Ltd. for Lifeward issuing to the Company a number of ordinary shares, no par value per share, of Lifeward, and pre-funded warrants to purchase the number of Lifeward Ord (closed 2026-03-25).
  evidence_excerpt: On March 25, 2026, Lifeward completed its acquisition of Oratech in accordance with the terms of the Share Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1176309/000121390026037474/0001213900-26-037474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.